2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 来源：新浪证券-红岸工作室 11月21日，海普瑞跌4.14%，成交额5327.83万元，换手率0.36%，总市值169.77亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 技术面：筹码平均交易成本为11.59元 该股筹码平均交易成本为11.59元，近期筹码减仓，但减仓程度减缓；目前股价靠近支撑位11.54，注意 支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 公司简介 资料显示，深圳市海普瑞药业集团股份有限公司位于广东省深圳市南山区松坪 ...

1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 来源：新浪证券-红岸工作室 11月20日，海普瑞涨0.42%，成交额3923.48万元，换手率0.26%，总市值177.10亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 区间今日近3日近5日近10日近20日主力净流入-169.92万-820.60万-879.98万-1334.90万-1 ...

Core Viewpoint - The article discusses the recent performance and business operations of Haiprime, highlighting its position in the pharmaceutical industry and the impact of currency depreciation on its revenue [2][3]. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][7]. - The company's main revenue sources include formulations (63.06%), CDMO services (18.59%), and heparin sodium and low molecular weight heparin raw materials (16.05%) [7]. Financial Performance - For the period from January to September 2025, Haiprime reported a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - As of September 30, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On November 17, Haiprime's stock price fell by 1.67%, with a trading volume of 49.2036 million yuan and a turnover rate of 0.32%, bringing the total market capitalization to 18.121 billion yuan [1]. - The stock has seen a net inflow of 1.2514 million yuan from major investors today, with no significant trend in buying or selling observed [4][5]. Technical Analysis - The average trading cost of Haiprime's shares is 11.59 yuan, with the stock price approaching a resistance level of 12.41 yuan, indicating potential for a price correction if it fails to break through this level [6]. Dividend Information - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Shareholder Structure - As of September 30, 2025, Haiprime had 27,000 shareholders, with the Hong Kong Central Clearing Limited being the eighth largest shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The average trading cost of the stock is 11.57 yuan, with the current stock price fluctuating between resistance at 12.33 yuan and support at 11.16 yuan [6]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300 [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On October 14, Haiprui's stock fell by 1.53%, with a trading volume of 59.5826 million yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 16.962 billion yuan [1].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin sodium raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 22, Haiprui's stock price fell by 0.81%, with a trading volume of 45.2628 million yuan and a market capitalization of 18.062 billion yuan [1]. - The stock has seen a net outflow of 3.1095 million yuan from major funds today, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price approaching a resistance level of 12.33 yuan, suggesting potential for a price correction if this level is not surpassed [6].

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on heparin, biopharmaceuticals, and innovative drugs, benefiting from the depreciation of the RMB and its strong overseas revenue [2][3]. Company Overview - Established in 1998 in Shenzhen, Haiprime operates with A+H dual financing platforms and is dedicated to providing high-quality and effective medications globally [2]. - The company’s main business segments include heparin products (20.25%), CDMO services (19.58%), and formulations (56.55%) [7]. Financial Performance - For the period from January to March 2025, Haiprime reported a revenue of 1.394 billion yuan, representing a year-on-year growth of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up by 1.00% [7]. - As of March 31, 2025, the company had a total market capitalization of 19.486 billion yuan [1]. Shareholder Information - As of March 31, 2025, Haiprime had 28,400 shareholders, an increase of 6.00% from the previous period [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the last three years [8]. Market Dynamics - Haiprime's overseas revenue accounted for 93.04% of its total revenue, benefiting from the depreciation of the RMB [3]. - The company is positioned within the pharmaceutical and biotechnology sectors, focusing on vaccines, innovative drugs, and raw materials [7]. Technical Analysis - The average trading cost of Haiprime's shares is 11.40 yuan, with the current stock price near a support level of 12.91 yuan [6].

Core Viewpoint - The article discusses the performance and business operations of Haiprui, a leading multinational pharmaceutical company, highlighting its revenue structure and market dynamics, particularly in relation to the depreciation of the Chinese yuan and its impact on overseas revenue [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and operates with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2]. - The company’s main business revenue composition includes: formulations (56.55%), heparin sodium and low molecular weight heparin raw materials (20.25%), CDMO (19.58%), and others (3.63%) [7]. - As of March 31, 2025, Haiprui reported a revenue of 1.394 billion yuan, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of 157 million yuan, up 1.00% year-on-year [7]. Financial Performance - Haiprui's overseas revenue accounts for 93.04% of its total revenue, benefiting from the depreciation of the yuan [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Dynamics - The stock experienced a decline of 1.40% on July 31, with a trading volume of 152 million yuan and a turnover rate of 0.91%, resulting in a total market capitalization of 19.647 billion yuan [1]. - The stock's average trading cost is 11.28 yuan, with recent buying activity observed, although the buying pressure is not strong [6]. - The stock is currently trading between resistance at 13.88 yuan and support at 12.41 yuan, indicating potential for range trading [6]. Institutional Holdings - As of March 31, 2025, Haiprui's top ten circulating shareholders include Hong Kong Central Clearing Limited and Innovation Drug, with increases in their holdings compared to the previous period [8].